Font Size: a A A
Keyword [Epidermal growth factor receptor tyrosine kinase]
Result: 41 - 60 | Page: 3 of 6
41. Efficiency And Safety Of Intercalated Treatment Of Icotinib With Chemotherapy In Patients Undergoing Resection Of EGFR Mutation-positive Non-small Cell Lung Cancer
42. The Role Of Autophagy In Modulation Of Resistance To Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors In Non-small Cell Lung Cancer
43. The Mechanism Of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibiter Resistance Induced By Hepatocyte Growth Factor In Non-small Cell Lung Cancer Cells
44. Circulating Plasma MicroRNAs As Potential Markers To Identify EGFR Mutation Status And To Monitor Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor Treatment In Patients With Advanced Non-small Cell Lung Cancer
45. Study Of 18F-FEA-erlotinib As An EGFR Targeting PET Imaging Agent
46. The Correlation Between EGFR Mutation Status And EGFR-TKI Efficacy In Non-small Cell Lung Cancer
47. Treatment And Prognosis Analysis Of 60 Cases Of Different EGFR Mutations Status In Non-small Cell Lung Cancer With Brain Metastasis
48. Intercalated Combination Of Chemotherapy And EGFR-TKIs Versus Chemotherapy Alone In The First-line Treatment Of Advanced Non-small Cell Lung Cancer: A Meta-analysis
49. Correlation Of EGFR Mutation With Brain Metastases In Non-small Cell Lung Cancer
50. Investigation Of EGFR Gene Mutation In Lung Squamous Cell Carcinoma And The Effect Of EGFR-TKI Treatment On Advanced EGFR Mutation
51. The Clinical Observation Of EGFR-TKI Rechallenge With Antiangiogenic Agents In Advanced NSCLC
52. The Differences Of Efficacy Of Chemotherapy And Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor In Advanced Lung Adenocarcinoma Patients Harboring 19del And L858R Mutation
53. Comparison Of The Clinical Outcome Of Gefitinib For Advanced Lung Adenocarcinoma With Positive Epidermal Growth Factor Receptor Mutated In Exon 21 Or 19 Del Between Patients Treated With First And Second Line Therapy
54. Role Of EMT In Radiosensitivity Of NSCLC With Acquired Resistance Of EGFR-TKI
55. Efficacy And Safety Of Stereotactic Body Radiation Therapy In The Management Of Oligopersistent Disease In Patients With Egfr Mutant Non-small Cell Lung Cancer During EGFR-TKIs Treatment
56. The Clinical Study And The Mechanism On The Reversion Of Acquired Resistance With The First Generation EGRF-TKIs For Advanced NSCLC Patients
57. Clinical Studies And Prognostic Analysis Of Leptomeningeal Metastases From Lung Cancer And Adenosquamous Lung Carcinoma
58. Establishment Of Third Generation EGFR-TKI Osimertinib Acquired Resistant NSCLC Cell Line And Preliminary Study On Resistance Mechanism
59. The Role Of Local Ablation Thepray For Advanced EGFR-mutant NSCLC Patients With Oligometastatic Disease Or Oligoprogressive Disease
60. Proteomics In Non-Small Cell Lung Cancer Patients For Prediction Of Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors And Chemotherapy
  <<First  <Prev  Next>  Last>>  Jump to